BRPI0517932A - muteìna humana de beta-interferon - Google Patents

muteìna humana de beta-interferon

Info

Publication number
BRPI0517932A
BRPI0517932A BRPI0517932-7A BRPI0517932A BRPI0517932A BR PI0517932 A BRPI0517932 A BR PI0517932A BR PI0517932 A BRPI0517932 A BR PI0517932A BR PI0517932 A BRPI0517932 A BR PI0517932A
Authority
BR
Brazil
Prior art keywords
interferon
beta
mutation
human
human beta
Prior art date
Application number
BRPI0517932-7A
Other languages
English (en)
Inventor
Moon Kyoung So
Jong Min Lee
Ji-Hye Yang
Ji Uk Yoo
Tae Ho Byun
Ji Tai Kim
Han Kyu Oh
Ho Chul Yoon
Ji Soo Ahn
Kyung Song
Jae Ho Jin
Young Kee Shin
Original Assignee
Young Kee Shin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Young Kee Shin filed Critical Young Kee Shin
Publication of BRPI0517932A publication Critical patent/BRPI0517932A/pt
Publication of BRPI0517932A8 publication Critical patent/BRPI0517932A8/pt
Publication of BRPI0517932B1 publication Critical patent/BRPI0517932B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MUTEìNA HUMANA DE BETA-INTERFERON. A presente invenção refere-se a uma muteina humana de beta-interferon. Em particular, a presente invenção se refere à muteina humana de beta-interferon dotada de uma ou duas cadeias adicionais de açúcar comparado com o beta-interferon natural de origem humana.
BRPI0517932-7A 2004-11-02 2005-11-02 Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma BRPI0517932B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2004-0088196 2004-11-02
KR1020040088196A KR100781666B1 (ko) 2004-11-02 2004-11-02 인간 인터페론-베타 변이체
PCT/KR2005/003665 WO2006049423A1 (en) 2004-11-02 2005-11-02 Human interferon-beta mutein

Publications (3)

Publication Number Publication Date
BRPI0517932A true BRPI0517932A (pt) 2008-10-21
BRPI0517932A8 BRPI0517932A8 (pt) 2018-05-02
BRPI0517932B1 BRPI0517932B1 (pt) 2021-10-19

Family

ID=36319397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517932-7A BRPI0517932B1 (pt) 2004-11-02 2005-11-02 Muteína humana de beta-interferon, polinucleotídeo, vetor de expressão, célula animal, método para preparação de referida muteína e composição farmacêutica compreedendo a mesma

Country Status (11)

Country Link
US (1) US8101716B2 (pt)
EP (1) EP1809661B1 (pt)
JP (1) JP4637913B2 (pt)
KR (1) KR100781666B1 (pt)
CN (1) CN101111519B (pt)
AT (1) ATE509951T1 (pt)
BR (1) BRPI0517932B1 (pt)
DK (1) DK1809661T3 (pt)
ES (1) ES2369088T3 (pt)
PT (1) PT1809661E (pt)
WO (1) WO2006049423A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN102260344A (zh) * 2010-05-26 2011-11-30 重庆富进生物医药有限公司 缺失型人β干扰素及其重组制备
DK2762489T3 (en) 2011-10-01 2018-07-02 Glytech Inc GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
SG11201507769SA (en) 2013-03-29 2015-10-29 Glytech Inc Polypeptide having sialylated sugar chains attached thereto
CN106132983B (zh) 2014-04-04 2021-03-26 阿雷斯贸易股份有限公司 新型IFN-β蛋白类似物
KR101671501B1 (ko) * 2014-07-24 2016-11-03 에이비온 주식회사 페길화된 인터페론-베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
KR101838919B1 (ko) 2015-03-03 2018-03-15 에이비온 주식회사 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
US20210009720A1 (en) * 2015-03-03 2021-01-14 Genopharm Inc. Human interferon-beta variant conjugated immunocytokine and method for preparing same
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
KR102666000B1 (ko) 2016-07-29 2024-05-14 서울대학교 산학협력단 cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물
KR101943160B1 (ko) 2016-10-06 2019-01-30 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
KR101955366B1 (ko) 2017-06-02 2019-03-07 인제대학교 산학협력단 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법
CN108117595B (zh) * 2018-02-28 2020-06-26 中国科学院微生物研究所 一种犬α干扰素的制备及其应用
KR20210021861A (ko) * 2019-08-19 2021-03-02 (주)제노팜 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
CN116075523A (zh) * 2020-04-29 2023-05-05 基因制药株式会社 具有融合的干扰素-β突变蛋白和抗体的重组蛋白以及包含其的药物组合物
JP2023524248A (ja) * 2020-04-29 2023-06-09 アビオン インク． 二重突然変異を有するヒトインターフェロン－ベータ変異体及びヒトインターフェロン－ベータ変異体の安全性を向上させる方法
EP4292604A4 (en) * 2021-01-13 2024-12-18 Abion Inc. METHOD OF PROPHYLACTIC ADMINISTRATION AGAINST A RESPIRATORY VIRUS, COMPRISING THE ADMINISTRATION OF INTERFERON BETA TO A SUBJECT POTENTIALLY INFECTED WITH A RESPIRATORY VIRUS
KR20240118230A (ko) * 2023-01-26 2024-08-05 에이비온 주식회사 인터페론 베타 건조 분말 제제 및 이의 제조방법
AU2024341598A1 (en) * 2023-09-12 2026-04-23 Heligenics Inc. Engineered interferon-beta proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
ATE386054T1 (de) 2002-08-31 2008-03-15 Cj Corp Glycosylierte humane interferon alpha isoform
EP1581631A4 (en) * 2002-10-01 2007-09-05 Xencor Inc INTERFERON VARIANTS HAVING IMPROVED PROPERTIES
KR100541850B1 (ko) * 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Also Published As

Publication number Publication date
US8101716B2 (en) 2012-01-24
EP1809661A1 (en) 2007-07-25
US20100003721A1 (en) 2010-01-07
ES2369088T3 (es) 2011-11-25
KR100781666B1 (ko) 2007-12-03
WO2006049423A1 (en) 2006-05-11
EP1809661B1 (en) 2011-05-18
BRPI0517932A8 (pt) 2018-05-02
KR20060039132A (ko) 2006-05-08
ATE509951T1 (de) 2011-06-15
JP2008518631A (ja) 2008-06-05
DK1809661T3 (da) 2011-09-05
PT1809661E (pt) 2011-09-05
EP1809661A4 (en) 2008-02-06
JP4637913B2 (ja) 2011-02-23
BRPI0517932B1 (pt) 2021-10-19
CN101111519B (zh) 2012-11-07
CN101111519A (zh) 2008-01-23

Similar Documents

Publication Publication Date Title
BRPI0517932A (pt) muteìna humana de beta-interferon
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
DK1841332T3 (da) Fortykningskomposition til dysfagi patienter
DK1966245T3 (da) Anti-CD19-Antistoffer med reduceret immunogenicitet
DE602006018689D1 (de) Inline Gefässversiegelungs- und trennungsinstrument
ATE394077T1 (de) Prolaps-reparatur
DK1807083T3 (da) Anvendelse af pirlindol til behandling af lidelser, der er kendetegnet ved proliferation af T-lymphocyter og/eller hyperproliferation af keratinocyter, især atopisk dermatitis og psoriasis
GB0515353D0 (en) Food
NO20075702L (no) Polymersjikt med lav fuktighet i ikke-autoklav fremgangsmate
DK2094992T3 (da) Ledkæde
MY146112A (en) Long-term feed - cancer patient
EP2073825A4 (en) CINNAMOMI AND PORIA COMPOSITION AND ITS USES
ATE491345T1 (de) Pasteurisierungsstabile stärkezusammensetzungen
DK2314668T3 (da) Gen-inaktiverede mutanter med ændret proteinproduktion
DE602005025158D1 (de) Zuckerrohrpflanze mit erhöhtem speicherkohlenhydratgehalt
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
ECSP077423A (es) Coadministración de tigeciclina y digoxin
PT1858481T (pt) Composições oftalmológicas e sua utilização
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
DE602005018095D1 (de) Transparente polyamidzusammensetzungen und damit hergestellte artikel
BRPI0606780A2 (pt) produtos alimentìcios
EP1865965A4 (en) 2-METHYLENE-19-NOR- (23S) -25-DEHYDRO-1-HYDROXYVITAMINE-D3-26,23-LACTONE AND 2-METHYLENE-19-NOR- (23R) -25-DEHYDRO-1-HYDROXYVITAMINE-D3- 26.23-lACTONE
ATE449332T1 (de) Alterungsbiomarker
ATE550969T1 (de) Regalelement
DE602006013497D1 (de) Erwendung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: REFERENCEBIOLABS CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: ABION INC. (KR)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: DESPACHO: PARA QUE A PETICAO NO 870190036018 DE 15/04/2019 POSSA SER ACATADA COMO RECURSOAO ARQUIVAMENTO, O DEPOSITANTE DEVERA REALIZAR O PAGAMENTO DO VALOR DA RETRIBUICAO DEVIDA.

B12C Appeal against dismissal [chapter 12.3 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.20 NA RPI NO 2594 DE 24/09/2020 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.